India's dual pricing pressures

Share this article:

India is struggling to keep its export drug business an enriching one. The Economic Times reports that international customers are aware of what the companies are charging in-country and now want similar prices for themselves. The Economic Times says companies are concerned that price parity would threaten their businesses, since India's price controls have driven prices down 60% for what the government considers essential medicines.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.